Missling can redeem himself and work towards his goal of getting the data to the regulatory authorities.
He needs to drive the process of getting the data out, make sure it is done and get it right the first time. He cannot afford to keep messing (communication or delivering questionable or incomplete data)
If 50mg (high dose) is supposed to be a lot better than the 30mg (low dose), then the focus should be two fold - to show the placebo vs 50 mg comparison and also do the 30mg vs 50mg comparison so that they can show the journey starting from placebo to 30mg to 50mg.
It is like telling a story and keeping listeners engaged from the start to the finish. (He has enough material to do a good job). He has to address all the misgivings the market and people (on social media) have shared during the past week. I would say it is a part and parcel of a good strategy.
News 
Market Data 
Discover 
